This trial is evaluating whether Cephalexin will improve 6 primary outcomes and 4 secondary outcomes in patients with Genetic Predisposition to Disease. Measurement will happen over the course of 90 days.
This trial requires 40 total participants across 2 different treatment groups
This trial involves 2 different treatments. Cephalexin is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 2 and have already been tested with other people.
"Clinical trial participation has increased over time and is now recommended for all patients when the cost-effectiveness of treatment outweighs the potential risks. Patients with concerns about the prolonged length of some treatments, or other severe side effects, may be less likely to participate, but this decision needs to be made in consultation with their clinician." - Anonymous Online Contributor
"Limited data suggest that cephalexin may be effective against infections caused by Enterobacteriaceae, Acinetobacter baumannii, Pseudomonas aeruginosa, Klebsiella pneumoniae, and Staphylococcus aureus. More research is needed to evaluate whether cephalexin has any effect against methicillin-resistant "Staphylococcus aureus" (MRSA), carbapenem-resistant P. aeruginosa, and vancomycin-resistant enterococci." - Anonymous Online Contributor
"Cephalexin improved health related quality of life in patients with respiratory tract infections. The use of cephalexin decreased patient's perception of symptoms when compared with placebo." - Anonymous Online Contributor
""Time to infection" is an important concept for health systems practitioners and public health workers. In reality however, it takes time to identify and control infections and to develop effective interventions that prevent them, especially when these are difficult to implement due to their complexity and cost. We discuss current evidence regarding the transmission of infectious diseases, and propose metrics and approaches that are useful for monitoring the effectiveness of such strategies within a health system context." - Anonymous Online Contributor
"Cephalexin is a broad spectrum antibiotic. It is used to treat bacterial infections of the urinary tract including cystitis, pyelonephritis, and bacteremia. Cephalexin is also effective against "Clostridium difficile" infection. Cephalexin is also effective for treating many penicillin allergies. Cephalexin is absorbed slowly through the GI tract, so it takes longer than other antibiotics to reach peak blood plasma concentrations. For this reason, cephalexin is often given as a single low dose instead of a course of treatment. The drug should be taken at least an hour before food to delay absorption." - Anonymous Online Contributor
"Cephalexin for therapeutic use is an effective antimicrobial agent against Gram-positive and gram-negative bacteria. It was first introduced in Japan in 1955 and its combination therapy with amoxicillin was approved by the FDA in 1965. At present, a combination therapy with cephalexin and penicillin G is widely used for treating infections caused by aerobic streptococci in hospitals. In addition, topical cephalexin ointment is widely used for treating bacterial skin infections such as impetigo bacillus, dermatophytosis and staphylococcal scalded skin syndrome. Because of these advantages, cephalexin is considered suitable for developing oral preparations." - Anonymous Online Contributor
"Cephalexin has demonstrated clinically beneficial effects in treating acute bacterial sinusitis. The mechanism responsible for its efficacy remains unknown. In vitro studies have shown that cephalexin alters membrane fluidity and permeability, which could account for its antibacterial activity." - Anonymous Online Contributor
"These treatments can be used to treat common infections such as herpes simplex, hepatitis A, influenza, chlamydia, HIV, and tuberculosis. Most patients will see their doctor, who can prescribe medication or make recommendations on how to take them." - Anonymous Online Contributor
"There is no standard definition of what ages mean when referring to people getting infections. Findings from a recent study shows that infections of many types occur across all ages (see table below). In this article we discuss how different age definitions may affect which diseases appear to be more common in certain groups of children. We also consider whether our attitudes and behaviors towards infectious diseases change according to age group." - Anonymous Online Contributor
"The overall prevalence of HAI and pneumonia among hospitalized adults was 11% and 9%, respectively; rates were highest among those with diabetes and Medicare insurance. Increased efforts are needed to improve HAI prophylaxis and adherence to guidelines in the prevention and management of HAI." - Anonymous Online Contributor
"The use of cephalexin in combination with antibiotics in patients hospitalized for pneumonia has been shown to decrease the risk of bacterial resistance to both cephalosporins and penicillins. Cephalexin should remain an important option in the empiric treatment of serious infections, particularly when carbapenem-resistant Gram-negative bacteria are suspected." - Anonymous Online Contributor